TB Alliance works with partners and stakeholders across a wide range of activities to advance the science for better, faster TB cures. After years of virtual meetings and engagements, in 2022 we were able to, once again, join many of our partners in-person around the world.

Connecting with Partners

TB Alliance colleagues joined in-person events around the world throughout 2022 to collaborate with partner organizations and other experts to help advance efforts to end TB and hold discussions on pandemic preparedness. Dr. Mel Spigelman, TB Alliance’s President and CEO, participated in the World Health Summit in October 2022 and joined partners from the WHO, the Stop TB Partnership, FIND, TAG, and others for an event on the importance of investing to end TB.

Advancing Health for All

More than three years after the start of the COVID-19 pandemic, the critical importance of investing in biomedical R&D to achieve Health for All has become more apparent than ever. The remarkable efforts witnessed throughout the COVID-19 pandemic also exposed serious gaps in equitable access to health tools, technologies, and services, which have had a negative impact on key areas of development. During the 77th Annual UN General Assembly Science Summit, TB Alliance joined MMV (Medicines for Malaria Venture) and DNDi (Drugs for Neglected Diseases initiative) in holding a side event on how scaling up investments in biomedical innovation and equitable access is necessary to achieve Health for All, which in turn drives sustainable development.

TB Alliance was Honored to Receive GHTC’s Innovating for Impact Partnership Award

The development and subsequent introduction of pretomanid and the BPaL regimen is a signature organizational achievement that wouldn’t have been possible without the committed and invaluable partnership of a constellation of funders, researchers, local communities, and clinical trial participants around the world. In December of 2022, TB Alliance and partners, including USAID and the US NIH were honored with the Global Health Technology Coalition’s Innovating for Impact Partnership Award, recognizing the importance of the development of this urgently needed new DR-TB therapy.

One of the interventions that we’re celebrating tonight – the extraordinary achievement of getting that combination of anti-tuberculous drugs. We have pretomanid, which we’re celebrating tonight, together with bedaquiline and linezolid, which has really transformed a field that has really been sleepy in the sense of not having the advances that we’ve had with other areas. We’re now essentially skyrocketing it into the 21st century.
— Dr. Anthony Fauci, M.D., Director of the National Institute of Allergy and Infectious Diseases

Our Financials

As the COVID-19 pandemic continued to demand extensive global health resources, and economic uncertainty and calls for austerity pervaded, those suffering from TB and DR-TB remain imperiled and all too neglected. TB research funding shortfalls remain profound, with research funded at approximately a third of Stop TB Partnership’s targets. Still, TB Alliance continued to advance new TB drug regimens and spearhead the introduction of pretomanid and the BPaL regimen at an unprecedented pace for a new TB therapy developed in the 21st century.

Download our 2022 Financial Statement

SPOTLIGHT: An Increasingly Global Workforce

TB Alliance is a not-for-profit product developer with a global mission—and we are continuing to reflect these principles in our organizational development and structure. This past year, we added new staff members based in strategic hubs from Washington DC, to Kyiv, Ukraine. With a need to ensure availability of our products wherever TB exists and with remote or hybrid teams becoming even more the norm, TB Alliance is increasingly capable of assembling global teams that include local expertise. The future is now—in both TB research itself and in how we work.

Annual Report 2022